The rest of the 100 (in alphabetical order): Gladys Nunez, principal, Amgen Ventures
Starting in a bioscientist position at Anglo-Swedish drugs group AstraZeneca after graduating from Southampton University, Gladys Nunez found her home at Amgen two years later when she joined the firm as a biochemist in 1997.
In 2002, Nunez joined the company’s business development unit, and has completed numerous deals for the company over the past 13 years, focused on discovery, development, and commercial applications in life sciences. She also managed Amgen’s Academic Alliance Group, an initiative to build bridges between academia and industry through the establishment of comprehensive academic alliances, for two years from 2008.
She said on her LinkedIn profile: “In the past couple of years, my focus has been supporting the advancement of Amgen’s Drug Delivery Strategy to support the therapeutic pipeline. In this role, I have been part of various strategic teams to support the establishment of many early-stage partnerships with key drug delivery organisations to support our goals.
“With my location in Cambridge, Massachusetts, I have worked with multiple east coast institutions, companies and venture capitalists to be a key contact person to support our business development goals. Recently, I have shifted formally into Amgen Ventures to help advance our early-stage investments in the technology and product areas.”
Since moving, Nunez has helped judge PathoVax’s innovation RGVax technology as the top winner at Harvard’s Healthcare Innovation and Commercialisation workshop.
For more than a decade, Amgen Ventures has invested in more than 30 emerging biotechnology companies to advance promising medicines and technologies.
